TL;DR
This study investigated PET/CT scan findings in patients who recently received mRNA COVID-19 vaccines, specifically looking at uptake in the deltoid muscle and axillary lymph nodes. They found that a significant portion of vaccinated individuals showed increased uptake in axillary lymph nodes, which was more common in younger, immunocompetent individuals, suggesting this could be a marker of immune response and a potential pitfall in cancer imaging.
What Problem Does This Paper Address?
As millions worldwide received mRNA COVID-19 vaccines, a critical question arose for clinicians: how would these vaccines affect imaging results, particularly in PET/CT scans, which are often used for cancer staging and monitoring? Specifically, the authors aimed to understand if recent vaccination could lead to false-positive findings, such as increased radiotracer uptake in lymph nodes, potentially mimicking malignancy and leading to unnecessary investigations or patient anxiety. They also sought to determine if patient factors like age and immune status influenced these imaging findings, providing valuable context for interpreting scans in the post-vaccination era.
Methods
The researchers conducted a retrospective analysis of prospectively collected data from adult patients who underwent PET/CT scans at their center between December 23, 2020, and January 27, 2021, and had received a COVID-19 mRNA vaccine. They collected data on patient demographics, clinical status, vaccination details (including timing and arm of injection), and current treatments. PET/CT scans were analyzed for increased uptake in the deltoid muscle (at the injection site) and ipsilateral axillary lymph nodes. Uptake was quantified using SUVmax and defined as positive if the ipsilateral-to-contralateral SUVmax ratio was at least 1.5. Statistical analysis, including multivariate logistic regression, was used to identify associations between PET/CT findings and patient characteristics like age, sex, immunosuppressive treatment, and hematologic disease.
Datasets
The study utilized data from 426 adult patients who underwent PET/CT scans at the Chaim Sheba Medical Center. This dataset was collected during the initial rollout of COVID-19 mRNA vaccinations in Israel. The primary imaging modality used was 18F-FDG PET/CT (88% of patients), with smaller numbers of patients undergoing scans with other tracers like 68Ga-DOTATATE, 18F-PSMA, and 18F-DOPA. No new benchmarks were introduced; the study focused on analyzing existing clinical data.
Key Insights and Ideas
- Vaccine-induced lymph node activation is common: The most striking finding is that a substantial percentage of vaccinated individuals exhibit increased PET/CT uptake in their axillary lymph nodes, a phenomenon that can mimic metastatic disease.
- Age and immune status are key predictors: Younger, immunocompetent individuals are more likely to show this lymph node uptake, suggesting it's a sign of a robust immune response. This inverse relationship with age and immunosuppression is a crucial takeaway.
- Deltoid muscle uptake is less informative: Unlike axillary lymph nodes, uptake in the deltoid muscle (the injection site) did not show a strong association with age or immune status, suggesting it might be more related to local inflammatory reactions.
- Timing and dose matter: The number of vaccine doses and the time elapsed since the last vaccination also influenced the likelihood of positive lymph node uptake, hinting at a dynamic immune response.
- Clinical implications for oncologists: This research is vital for oncologists and nuclear medicine physicians to avoid misinterpreting these vaccine-related findings as malignancy, potentially preventing unnecessary biopsies and patient distress.
Key Results
- Out of 426 vaccinated patients, 45% showed positive axillary lymph node uptake on 18F-FDG PET/CT.
- This uptake was significantly inversely associated with patient age (OR, 0.57), immunosuppressive treatment (OR, 0.37), and hematologic disease (OR, 0.44).
- The number of vaccine doses was strongly associated with increased odds of positive lymph node uptake (OR, 7.53 for second dose).
- The time since the last vaccination also increased the odds of positive lymph node uptake (OR, 1.53 per scaled day).
- No significant association was found between deltoid muscle uptake and age or immune status.
Limitations and Future Work
The authors acknowledge several limitations:
- Vaccine specificity: The study focused solely on Pfizer-BioNTech mRNA vaccines. It's unknown if other mRNA vaccines or different vaccine platforms (e.g., viral vectors) would elicit similar PET/CT findings.
- Immunocompromised classification: The criteria for classifying patients as immunocompromised might not capture all nuances, potentially leading to misclassification.
- Tracer variety: The statistical analysis for associations was primarily based on 18F-FDG scans due to the small number of scans with other tracers. Further research is needed for these tracers.
- Short follow-up: The study was conducted over a short period (37 days), and while uptake was observed up to 34 days post-vaccination, the long-term trend and resolution of this uptake are not fully understood.
Future work could involve studying other vaccine types, refining immunocompromised classifications, and conducting longitudinal studies to track the duration and resolution of vaccine-related PET/CT findings. The authors also suggest that oncologists might consider advising breast cancer patients to get vaccinated on their healthy side to potentially avoid unnecessary biopsies.
Summary updated